Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$4.96
-1.6%
$4.47
$3.42
$8.14
$278.82M1.941.63 million shs664,250 shs
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
$1.63
+14.0%
$1.41
$1.03
$2.57
$325.67M1.221.53 million shs2.44 million shs
Atyr PHARMA INC stock logo
ATYR
Atyr PHARMA
$3.00
-1.0%
$3.26
$1.42
$4.66
$267.01M0.79917,695 shs1.38 million shs
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
$0.88
+19.8%
$0.81
$0.52
$5.17
$74.11M1.771.11 million shs1.75 million shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
-2.33%+9.80%+18.59%-23.87%-28.00%
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
+1.42%+2.88%+3.62%-37.00%-25.13%
Atyr PHARMA INC stock logo
ATYR
Atyr PHARMA
-8.46%-4.11%+0.66%-15.60%+302,999,900.00%
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
-10.07%-26.26%+22.80%-57.87%-83.11%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.4412 of 5 stars
0.02.00.00.02.40.80.6
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
2.4425 of 5 stars
3.71.00.00.02.72.50.6
Atyr PHARMA INC stock logo
ATYR
Atyr PHARMA
2.7239 of 5 stars
3.61.00.00.03.23.30.6
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
4.1659 of 5 stars
4.12.00.04.71.51.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
3.67
Strong BuyN/AN/A
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
3.33
Buy$10.50544.17% Upside
Atyr PHARMA INC stock logo
ATYR
Atyr PHARMA
3.14
Buy$18.60520.00% Upside
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
2.13
Hold$6.14599.24% Upside

Current Analyst Ratings Breakdown

Latest STRO, ATYR, ATAI, and ACB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/13/2025
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/29/2025
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$2.00 ➝ $2.00
3/19/2025
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
3/17/2025
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$12.00 ➝ $2.00
3/14/2025
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$2.00
3/14/2025
Atyr PHARMA INC stock logo
ATYR
Atyr PHARMA
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$35.00 ➝ $35.00
3/14/2025
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
3/14/2025
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
Citizens Jmp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
3/14/2025
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Neutral$8.00 ➝ $2.00
3/14/2025
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Underperform$11.00 ➝ $1.00
2/18/2025
Atyr PHARMA INC stock logo
ATYR
Atyr PHARMA
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$320.81M0.87$0.19 per share26.35$8.18 per share0.61
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
$308K1,057.36N/AN/A$1.47 per share1.11
Atyr PHARMA INC stock logo
ATYR
Atyr PHARMA
$235K1,136.22N/AN/A$1.54 per share1.95
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
$66.43M1.12N/AN/A$2.45 per share0.36
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
-$48.62M$0.0599.2211.27N/A0.42%0.59%0.42%6/19/2025 (Estimated)
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
-$40.22M-$0.93N/AN/AN/AN/A-65.75%-52.71%N/A
Atyr PHARMA INC stock logo
ATYR
Atyr PHARMA
-$50.39M-$0.81N/AN/AN/AN/A-79.44%-59.16%N/A
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
-$106.79M-$2.98N/AN/AN/A-77.01%-101.89%-28.69%N/A

Latest STRO, ATYR, ATAI, and ACB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
-$0.19-$0.15+$0.04-$0.15N/A$1.56 million
5/8/2025Q1 2025
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
-$0.63-$0.91-$0.28-$0.91$11.61 million$17.40 million
5/7/2025Q1 2025
Atyr PHARMA INC stock logo
ATYR
Atyr PHARMA
-$0.19-$0.17+$0.02-$0.17N/AN/A
3/17/2025Q4 2024
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
-$0.14-$0.24-$0.10-$0.24$0.30 million($0.01) million
3/13/2025Q4 2024
Atyr PHARMA INC stock logo
ATYR
Atyr PHARMA
-$0.23-$0.18+$0.05-$0.18$0.02 millionN/A
3/13/2025Q4 2024
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
-$0.86-$2.96-$2.10-$0.89$10.44 million$14.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
N/AN/AN/AN/AN/A
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
N/AN/AN/AN/AN/A
Atyr PHARMA INC stock logo
ATYR
Atyr PHARMA
N/AN/AN/AN/AN/A
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.07
3.30
1.60
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
0.14
5.81
5.81
Atyr PHARMA INC stock logo
ATYR
Atyr PHARMA
0.02
5.41
5.41
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
N/A
3.09
3.09

Institutional Ownership

CompanyInstitutional Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
47.63%
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
28.41%
Atyr PHARMA INC stock logo
ATYR
Atyr PHARMA
61.72%
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
96.99%

Insider Ownership

CompanyInsider Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.01%
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
31.20%
Atyr PHARMA INC stock logo
ATYR
Atyr PHARMA
3.70%
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
3.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
1,34056.21 million54.85 millionOptionable
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
80199.80 million115.45 millionOptionable
Atyr PHARMA INC stock logo
ATYR
Atyr PHARMA
5389.00 million80.84 millionOptionable
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
24084.36 million77.59 millionOptionable

Recent News About These Companies

Sutro Biopharma downgraded to Neutral from Buy at H.C. Wainwright
Sutro Biopharma presents expanded data from REFRalphaME-01 trial

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Aurora Cannabis stock logo

Aurora Cannabis NASDAQ:ACB

$4.96 -0.08 (-1.59%)
As of 04:00 PM Eastern

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Atai Life Sciences stock logo

Atai Life Sciences NASDAQ:ATAI

$1.63 +0.20 (+13.99%)
As of 04:00 PM Eastern

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Atyr PHARMA stock logo

Atyr PHARMA NASDAQ:ATYR

$3.00 -0.03 (-0.99%)
As of 04:00 PM Eastern

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Sutro Biopharma stock logo

Sutro Biopharma NASDAQ:STRO

$0.88 +0.15 (+19.85%)
As of 04:00 PM Eastern

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.